RxDoctor Payments Data

John Weippert, DO

Internal Medicine · Warren, OHNPI 1780903518

Payments from drug & device makers

$18,712in general payments, 2019–2025

Across 1,233 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$1K
  • Daiichi Sankyo Inc.$839
  • QOL Medical, LLC$758
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$18,59799%
  • Education$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$18,712 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$77,365
Medicare patients
325
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$306,993
ZenpepLipase/Protease/Amylase20$113,048
LinzessLinaclotide184$106,875
XifaxanRifaximin33$102,914
Humira(Cf) PenAdalimumab11$75,155
TrulancePlecanatide76$47,743
MotegrityPrucalopride Succinate41$29,546
IbsrelaTenapanor Hcl12$20,254
MovantikNaloxegol Oxalate19$7,995
Pantoprazole Sodium873$6,950
Dexlansoprazole DrDexlansoprazole37$6,822
Mesalamine14$6,258
Famotidine532$4,915
Lubiprostone41$3,612
Mesalamine ErMesalamine13$3,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,201$306,99312 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$2,395$150,657109 claims
Aimmune Therapeutics, Inc.Zenpep$202$113,04820 claims
AbbVieLinzess$6,386$106,875184 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,687$29,54641 claims
Ardelyx, Inc.Ibsrela$456$20,25412 claims
Redhill Biopharma Inc.Movantik$280$7,99519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Warren

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →